1,2-distearoylphosphatidylethanolamine has been researched along with paclitaxel in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gill, KK; Kaddoumi, A; Nazzal, S | 2 |
| Cai, L; Chen, L; Chen, X; Duan, X; Li, X; Qian, Z; Qiu, N; Wang, W; Wang, X; Wei, Y; Wen, J; Yang, L | 1 |
| Torchilin, VP; Wu, H; Zhu, L | 1 |
| Jain, AK; Jain, N; Mishra, DK; Rajoriya, V; Sahu, PK | 1 |
| Amini, M; Dinarvand, R; Dorkoosh, FA; Khoshayand, MR; Saadat, E | 1 |
| Meng, H; Xu, Y | 1 |
| Cao, J; Gu, Z; He, B; He, X; Jiang, L; Li, L; Pan, W; Yi, Q | 1 |
| Cao, Z; Gao, H; He, Q; Li, J; Liu, Y; Long, Y; Qian, J; Qiu, Y; Shi, K; Wang, Y; Yang, B; Yang, P; Zhang, Q; Zhang, Z | 1 |
| Bhadra, MP; Bhadra, U; Garikapati, KR; Reddy, BV; Reddy, SG; Reddy, TL; Yadav, JS | 1 |
| Chen, Z; Li, C; Li, L; Liu, B; Wang, F | 1 |
| Fumoto, S; Kawakami, S; Kuroda, N; Miyamoto, H; Nishida, K; Peng, JQ; Suga, T | 1 |
| Fu, L; Liao, J; Ouyang, J; Tang, A; Wang, D; Yang, H | 1 |
| Huang, W; Wang, P; Wang, Y; Xia, X; Yan, D | 1 |
14 other study(ies) available for 1,2-distearoylphosphatidylethanolamine and paclitaxel
| Article | Year |
|---|---|
Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Lung; Male; Micelles; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tissue Distribution; Trachea | 2011 |
Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Micelles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Sesquiterpenes; Vitamin E | 2012 |
Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Binding Sites; Cell Line, Tumor; Cholesterol; Drug Stability; Female; Humans; Ligands; Liposomes; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Peptides; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Random Allocation; Receptors, Fibroblast Growth Factor; Tissue Distribution | 2012 |
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cytosol; Diffusion; Hydrogen-Ion Concentration; Mice; Micelles; Nanocapsules; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Proteins | 2013 |
Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
Topics: Absorption, Physiological; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; Drug Storage; Humans; Lung Neoplasms; Male; Mannose; Nanoparticles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Pulmonary Alveoli; Rats; Surface Properties; Tissue Distribution; Triglycerides; Xenograft Model Antitumor Assays | 2015 |
Synthesis and optimization of a novel polymeric micelle based on hyaluronic acid and phospholipids for delivery of paclitaxel, in vitro and in-vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemical Phenomena; Drug Carriers; Drug Compounding; Drug Stability; Drug Storage; Fluorescent Dyes; Hyaluronic Acid; Micelles; Models, Chemical; Optical Imaging; Paclitaxel; Particle Size; Phosphatidylethanolamines; Rats; Solubility; Tissue Distribution; Whole Body Imaging | 2014 |
Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma; Cell Line, Tumor; Cholesterol; Drug Compounding; Drug Liberation; Half-Life; Humans; Injections, Intravenous; Liposomes; Liver; Lung Neoplasms; Mice; Paclitaxel; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Rats, Sprague-Dawley; Spleen; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Molecular Sequence Data; Paclitaxel; Peptides; Phosphatidylethanolamines; Protons | 2015 |
A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Coculture Techniques; Drug Liberation; Female; Humans; Hydrogen-Ion Concentration; Integrin alphaVbeta3; Liposomes; Melanoma, Experimental; Mice, Inbred C57BL; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols | 2015 |
Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Hydrogen-Ion Concentration; Imidazoles; Liposomes; Melanoma, Experimental; Mice; Nanoparticles; Paclitaxel; Phosphatidylethanolamines; Proto-Oncogene Proteins c-bcl-2; Pyrones; RNA, Small Interfering; Skin Neoplasms; Tumor Burden | 2016 |
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Hyaluronic Acid; Lipids; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Poloxamer; Tissue Distribution; Uterine Cervical Neoplasms | 2017 |
Targeted co-delivery of protein and drug to a tumor in vivo by sophisticated RGD-modified lipid-calcium carbonate nanoparticles.
Topics: Animals; Antineoplastic Agents; Calcium Carbonate; Carbocyanines; Cell Line, Tumor; Cell Membrane Permeability; Drug Liberation; Drug Therapy, Combination; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Lipids; Male; Mice; Molecular Targeted Therapy; Nanocapsules; Neoplasms, Experimental; Oligopeptides; Optical Imaging; Paclitaxel; Phosphatidylethanolamines; Serum Albumin, Bovine; Superoxide Dismutase; Surface Properties | 2019 |
Surface modified halloysite nanotubes with different lumen diameters as drug carriers for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell Survival; Drug Carriers; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Nanotubes; Paclitaxel; Particle Size; Phosphatidylethanolamines; Porosity; Surface Properties | 2021 |
Redox-responsive drug-inhibitor conjugate encapsulated in DSPE-PEG
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel | 2023 |